| Pharmaceutical Information |
| Drug Name |
Fluoxymesterone |
| Drug ID |
BADD_D00934 |
| Description |
An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. |
| Indications and Usage |
In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal. |
| Marketing Status |
approved; illicit |
| ATC Code |
G03BA01 |
| DrugBank ID |
DB01185
|
| KEGG ID |
D00327
|
| MeSH ID |
D005474
|
| PubChem ID |
6446
|
| TTD Drug ID |
D0L2LS
|
| NDC Product Code |
64181-0082; 65089-0052 |
| UNII |
9JU12S4YFY
|
| Synonyms |
Fluoxymesterone | Fluoximesteron | Halotestin | Stenox | Android-F | Android F |
|
| Chemical Information |
| Molecular Formula |
C20H29FO3 |
| CAS Registry Number |
76-43-7 |
| SMILES |
CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C)O)C)O)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
